AstraZeneca is currently recruiting participants for a Phase 3 clinical trial titled DESTINY-Biliary Tract Cancer-01, which aims to assess the efficacy and safety of Trastuzumab D ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

The HER2-specific tyrosine kinase inhibitor tucatinib, combined with trastuzumab and capecitabine, showed improved survival as compared with trastuzumab and capecitabine in patients with heavily ...

Trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo) in combination with pertuzumab (Perjeta; Genentech) demonstrated significantly longer progression-free survival (PFS) compared with the ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.